Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting.

Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting. - Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034509

Enrollment

Registered

2018-11-01

Start date

2018-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline resectable pancreatic cancer

Interventions

Neoadjuvant chemotherapy with FOLFIRINOX therapy followed by radical surgery

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) invasive ductal carcinoma of the pancreas 2) no distant metastasis 3) R0/1 resectable 4) borderline resectable Pancreatic cancer 5) all adult who anticipate to undergo pancreatectomy 6) no prior therapy 7) ECOG performance status of 0 or 1 8) adequate organ function 9) oral intake is possible 10) written informed consent

Exclusion criteria

Exclusion criteria: 1) Chemotherapy naiive for pancreatic cancer 2) Active double cancer 3) Active infection 4) HBs antigen positive 5) patients are using flucytosine, phenytoin, warfarin 6) pregnant females, possibly pregnant females

Design outcomes

Primary

Measure	Time frame
overall survival	—

Secondary

Measure	Time frame
recurrence free survival, R0 resection rate	—

Countries

Japan

Contacts

Public ContactRiki Ninomiya

Saitama Medical Center, Saitama Medical University Department of Hepatobiliary Pancreatic Surgery

rickynino9222@gmail.com049-228-3400

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026